Immunity and inflammation in status epilepticus and its sequelae

Possibilities for therapeutic application

Annamaria Vezzani, Raymond Dingledine, Andrea O. Rossetti

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Status epilepticus (SE) is a life-threatening neurological emergency often refractory to available treatment options. It is a very heterogeneous condition in terms of clinical presentation and causes, which besides genetic, vascular and other structural causes also include CNS or severe systemic infections, sudden withdrawal from benzodiazepines or anticonvulsants and rare autoimmune etiologies. Treatment of SE is essentially based on expert opinions and antiepileptic drug treatment per se seems to have no major impact on prognosis. There is, therefore, urgent need of novel therapies that rely upon a better understanding of the basic mechanisms underlying this clinical condition. Accumulating evidence in animal models highlights that inflammation ensuing in the brain during SE may play a determinant role in ongoing seizures and their long-term detrimental consequences, independent of an infection or auto-immune cause; this evidence encourages reconsideration of the treatment flow in SE patients.

Original languageEnglish
Pages (from-to)1081-1092
Number of pages12
JournalExpert Review of Neurotherapeutics
Volume15
Issue number9
DOIs
Publication statusPublished - Sep 2 2015

Fingerprint

Status Epilepticus
Immunity
Inflammation
Anticonvulsants
Therapeutics
Expert Testimony
Infection
Benzodiazepines
Blood Vessels
Seizures
Emergencies
Animal Models
Brain

Keywords

  • animal models
  • anti-inflammatory treatments
  • bloodbrain barrier
  • comorbidities
  • COX-2
  • cytokines
  • neurodegeneration
  • outcome
  • prognosis
  • refractory status epilepticus
  • seizures

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)

Cite this

Immunity and inflammation in status epilepticus and its sequelae : Possibilities for therapeutic application. / Vezzani, Annamaria; Dingledine, Raymond; Rossetti, Andrea O.

In: Expert Review of Neurotherapeutics, Vol. 15, No. 9, 02.09.2015, p. 1081-1092.

Research output: Contribution to journalArticle

@article{6befd6fcf0bd440f80113b9bc8cf2088,
title = "Immunity and inflammation in status epilepticus and its sequelae: Possibilities for therapeutic application",
abstract = "Status epilepticus (SE) is a life-threatening neurological emergency often refractory to available treatment options. It is a very heterogeneous condition in terms of clinical presentation and causes, which besides genetic, vascular and other structural causes also include CNS or severe systemic infections, sudden withdrawal from benzodiazepines or anticonvulsants and rare autoimmune etiologies. Treatment of SE is essentially based on expert opinions and antiepileptic drug treatment per se seems to have no major impact on prognosis. There is, therefore, urgent need of novel therapies that rely upon a better understanding of the basic mechanisms underlying this clinical condition. Accumulating evidence in animal models highlights that inflammation ensuing in the brain during SE may play a determinant role in ongoing seizures and their long-term detrimental consequences, independent of an infection or auto-immune cause; this evidence encourages reconsideration of the treatment flow in SE patients.",
keywords = "animal models, anti-inflammatory treatments, bloodbrain barrier, comorbidities, COX-2, cytokines, neurodegeneration, outcome, prognosis, refractory status epilepticus, seizures",
author = "Annamaria Vezzani and Raymond Dingledine and Rossetti, {Andrea O.}",
year = "2015",
month = "9",
day = "2",
doi = "10.1586/14737175.2015.1079130",
language = "English",
volume = "15",
pages = "1081--1092",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - Immunity and inflammation in status epilepticus and its sequelae

T2 - Possibilities for therapeutic application

AU - Vezzani, Annamaria

AU - Dingledine, Raymond

AU - Rossetti, Andrea O.

PY - 2015/9/2

Y1 - 2015/9/2

N2 - Status epilepticus (SE) is a life-threatening neurological emergency often refractory to available treatment options. It is a very heterogeneous condition in terms of clinical presentation and causes, which besides genetic, vascular and other structural causes also include CNS or severe systemic infections, sudden withdrawal from benzodiazepines or anticonvulsants and rare autoimmune etiologies. Treatment of SE is essentially based on expert opinions and antiepileptic drug treatment per se seems to have no major impact on prognosis. There is, therefore, urgent need of novel therapies that rely upon a better understanding of the basic mechanisms underlying this clinical condition. Accumulating evidence in animal models highlights that inflammation ensuing in the brain during SE may play a determinant role in ongoing seizures and their long-term detrimental consequences, independent of an infection or auto-immune cause; this evidence encourages reconsideration of the treatment flow in SE patients.

AB - Status epilepticus (SE) is a life-threatening neurological emergency often refractory to available treatment options. It is a very heterogeneous condition in terms of clinical presentation and causes, which besides genetic, vascular and other structural causes also include CNS or severe systemic infections, sudden withdrawal from benzodiazepines or anticonvulsants and rare autoimmune etiologies. Treatment of SE is essentially based on expert opinions and antiepileptic drug treatment per se seems to have no major impact on prognosis. There is, therefore, urgent need of novel therapies that rely upon a better understanding of the basic mechanisms underlying this clinical condition. Accumulating evidence in animal models highlights that inflammation ensuing in the brain during SE may play a determinant role in ongoing seizures and their long-term detrimental consequences, independent of an infection or auto-immune cause; this evidence encourages reconsideration of the treatment flow in SE patients.

KW - animal models

KW - anti-inflammatory treatments

KW - bloodbrain barrier

KW - comorbidities

KW - COX-2

KW - cytokines

KW - neurodegeneration

KW - outcome

KW - prognosis

KW - refractory status epilepticus

KW - seizures

UR - http://www.scopus.com/inward/record.url?scp=84940655834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940655834&partnerID=8YFLogxK

U2 - 10.1586/14737175.2015.1079130

DO - 10.1586/14737175.2015.1079130

M3 - Article

VL - 15

SP - 1081

EP - 1092

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 9

ER -